Vnitr Lek 2010, 56(Suppl 1):27-30

Thromocytopenia in malignancy. Introduction into the topic: causes, prognostic and therapeutic implications

E. Faber
Hemato-onkologická klinika Lékařské fakulty UP a FN Olomouc, přednosta prof. MUDr. Karel Indrák, DrSc.

Incidence of thrombocytopenia in malignancy markedly differ according its pathogenesis. Clinical importance of thrombocytopenia including development of serious bleeding is not directly associated with the number of platelets but frequently with other circumstances or complications. Prognosis of patients with thrombocytopenia caused by marrow metastatic infiltration, disseminated coagulopathy or microangiopathy is generally very serious. The treatment of thrombocytopenia in malignancy should be aimed towards elimination of its cause.

Keywords: thrombocytopenia; cancer; prognosis

Received: March 30, 2010; Published: February 1, 2010  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Faber E. Thromocytopenia in malignancy. Introduction into the topic: causes, prognostic and therapeutic implications. Vnitr Lek. 2010;56(Supplementum 1):27-30.
Share...
Download citation
  • BibTeX (.bib)
  • Bookends (.ris)
  • EasyBib (.ris)
  • EndNote (.enw)
  • EndNote 8 (.xml)
  • ISI WoS (.isi)
  • Medlars (.medlars)
  • Mendeley (.ris)
  • MODS (.xml)
  • Papers (.ris)
  • RefWorks (.txt)
  • RefManager (.ris)
  • RIS (.ris)
  • MS Word (.xml)
  • Zotero (.ris)
    • Open full article

    References

    1. Warketin TE, Kelton JG. Thrombocytopenia due to platelet destruction and hypersplenism. In: Hoffman R, Benz Jr EJ, Shattil SJ et al. Hematology basic principles and practice 4th Edition. Philadelphia: Elsevier Churchill Livingstone 2005: 2305-2325.
    2. Aster RH. Pooling of platelets in the spleen: Role in the pathogenesis of "hypersplenic" thrombocytopenia. J Clin Invest 1966; 45: 645-657. Go to original source... Go to PubMed...
    3. Belt RJ, Leite C, Haas CD et al. Incidence of hemorrhagic complications in patients with cancer. J Am Med Assoc 1978; 239: 2571-2574. Go to original source... Go to PubMed...
    4. Dutcher JP, Schiffer CA, Aisner J et al. Incidence of thrombocytopenia and serious hemorrhage among patients with solid tumors. Cancer 1984; 53: 557-562. Go to original source...
    5. Goldberg GL, Gibbon DG, Smith HO et al. Clinical impact of chemotherapy-induced thrombocytopenia in patients with gynecolocig cancer. J Clin Oncol 1994; 12: 2317-2320. Go to original source... Go to PubMed...
    6. Avvisati G, Tirindelli MC, Annibali O. Thrombocytopenia and hemorrhagic risk in cancer patients. Crit Rew Oncol Hematol 2003; 48S: S13-S16. Go to original source... Go to PubMed...
    7. Medina PJ, Sipols JM, George JN. Drug-associated thrombotic thrombocytopenic purpura - hemolytic uremic syndrome. Curr Opin Hematol 2001; 8: 286-293. Go to original source... Go to PubMed...
    8. Sallah S, Wan J, Nguyen N et al. Disseminated intravascular coagulation in solid tumors: clinical and pathologic study. Thromb Haemost 2001; 86: 828-833. Go to original source... Go to PubMed...
    9. Forman RB, Benkel SA, Novik Y et al. Presence of ADAMTS13 activity in a patient with metastatic cancer and thrombotic microangiopathy. Acta Hematol 2003; 109: 150-152. Go to original source... Go to PubMed...
    10. Cervantes F, Pereira A, Esteve J et al. Identification of "short-lived" and "long-lived" patients at presentation of idiopathic myelofibrosis. Br J Haematol 1997; 97: 635-640. Go to original source... Go to PubMed...
    11. Hasselbalch H, Jensen BA. Prognostic factors in idiopathic myelofibrosis: a simple scoring system with prognostic significance. Eur J Haematol 1990; 44: 172-178. Go to original source... Go to PubMed...
    12. Sokal JE, Cox EB, Baccarani M et al. Prognostic discrimination in "good-risk" chronic granulocytic leukemia. Blood 1984; 63: 789-799. Go to original source...
    13. Hasford J, Pfirrmann M, Hehlmann R et al. A new prognostic score for survival of patients with chronic myeloid leukemia treated with interferon alfa. J Natl Canc Inst 1998; 90: 850-858. Go to original source... Go to PubMed...
    14. Hubáček J, Faber E, Slezák P et al. Mikroangiopatická hemolytická anemie jako první projev metastazujícího karcinomu. Prakt Lék 1996; 76: 555-558.
    15. Tomšová M, Žák P. Mikroangiopatická hemolytická anémie s trombocytopenií (cr-TTP) u pacienta s generalizovaným adenokarcinomem žaludku. Čs Patol 2003; 39: 26-30.
    16. Lesesne JB, Rothschild N, Erickson B et al. Cancer-associated hemolytic uremic syndrome. Analysis of 85 cases from a national registry. J Clin Oncol 1989; 7: 781-789. Go to original source... Go to PubMed...
    17. von Baeyer H. Plasmapheresis in thrombotic microangiopathy-associated syndromes: Review of of outcome data derived from clinical trials and open studies. Ther Apheresis 2002; 6: 320-328. Go to original source... Go to PubMed...
    18. Isaacs C, Robert NJ, Bailey FA et al. Randomized placebo-controlled study of recombinant human interleukin-11 to prevent chemotherapy-induced thrombocytopenia in patients with breast cancer receiving dose-intensive cyclophosphamide and doxorubicin. J Clin Oncol 1997; 15: 3368-3377. Go to original source... Go to PubMed...
    19. Tepler I, Elias L, Smith II et al. A randomized placebo-controlled trial of recombinant human interleukin-11 in cancer patients with severe thrombocytopenia due to chemotherapy. Blood 1996; 87: 3607-3614.
    20. Aribi A, Kantarjian H, Koller C et al. Effect of interleukin 11 on thrombocytopenia associated with tyrosine kinase inhibitor therapy in patients with chronic myeloid leukemia. Cancer 2008; 113: 1338-1343. Go to original source... Go to PubMed...

    Return to the content


    Vnitřní lékařství

    Madam, Sir,
    please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
    Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

    I declare:

    1. that I have met the above instruction
    2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited

    No
    Yes

    If your statement is not true, please be aware
    that brings the risk of danger to their health or the health of others.